Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 8/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339678 | 0.91 | HTR2A (0.36) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6636325 | 0.91 | FPR2 (0.38) | MEN1KMT2AACACBFPR2PROKR1 | |
| SCHEMBL6665547 | 0.90 | SCN9A (0.34) | MEN1KMT2AACACBFPR2PROKR1 | |
| SCHEMBL5331514 | 0.87 | NTRK1 (0.42) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5221538 | 0.84 | MAPT (0.38) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5221796 | 0.84 | MAPT (0.36) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5222870 | 0.83 | MAPT (0.35) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5222865 | 0.83 | MAPT (0.35) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5218156 | 0.81 | MAPK14 (0.41) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6623481 | 0.81 | MAPT (0.36) | MAPTMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | MAPT 4292/4885MAPK13 1871/4885MAPK12 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.